Open Access Short report

Development and promotion in translational medicine: perspectives from 2012 sino-american symposium on clinical and translational medicine

Mengjia Qian1, Duojiao Wu1, Ena Wang3, Francesco M Marincola3, Wei Wang45, William Rhodes6, Michael Liebman7, Chunxue Bai2, Ching-Wan Lam8, Gyorgy Marko-Varga9, Thomas E Fehniger9, Roland Andersson9 and Xiangdong Wang12*

Author Affiliations

1 Biomedical Research Center, Shanghai, China

2 Department of Pulmonary Medicine, Fudan University School of Medicine, Zhongshan Hospital, Shanghai, China

3 Infectious Disease and Immunogenetics Section (IDIS), Department of Transfusion Medicine, Clinical Center and Center for Human Immunology (CHI), NIH, Bethesda, MD, USA

4 School of Medical Sciences, Edith Cowan University, Perth, Australia

5 Beijing Municipal Key Laboratory of Clinical Epidemiology, Graduate University of the Chinese Academy of Sciences, Beijing, China

6 Becton Dickinson and Co, Franklin Lakes, New Jersey, USA

7 IPQ Analytics, LLC and of Strategic Medicine, Inc, Strategic Medicine, BV, The Hague, NL

8 Department of Pathology, The University of Hong Kong, Hong Kong, China

9 Department of Surgery, Clinical Sciences, Medical Faculty, Lund University, Lund, Sweden

For all author emails, please log on.

Clinical and Translational Medicine 2012, 1:25  doi:10.1186/2001-1326-1-25

Published: 24 October 2012

Abstract

Background

Clinical translational medicine (CTM) is an emerging area comprising multidisciplinary research from basic science to medical applications and entails a close collaboration among hospital, academia and industry.

Findings

This Session focused discussing on new models for project development and promotion in translational medicine. The conference stimulated the scientific and commercial communication of project development between academies and companies, shared the advanced knowledge and expertise of clinical applications, and created the environment for collaborations.

Conclusions

Although strategic collaborations between corporate and academic institutions have resulted in a state of resurgence in the market, new cooperation models still need time to tell whether they will improve the translational medicine process.